Loading clinical trials...
Loading clinical trials...
A Phase 1/2 Randomized, Observer-blinded, Multi-country Study to Evaluate Safety and Immunogenicity of Investigational Adjuvanted Human Papillomavirus Vaccine in Females (16 to 26 Years of Age)
Conditions
Interventions
HPV9 High formulation
HPV9 Medium formulation
+2 more
Locations
68
United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
Wheat Ridge, Colorado, United States
GSK Investigational Site
Coral Gables, Florida, United States
GSK Investigational Site
Kissimmee, Florida, United States
GSK Investigational Site
Miami, Florida, United States
Start Date
August 22, 2022
Primary Completion Date
February 23, 2024
Completion Date
February 25, 2024
Last Updated
February 3, 2025
NCT04712851
NCT05266898
NCT04783805
NCT07059819
NCT02328872
NCT02149030
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions